$VOR

Vor Bio completed enrollment in its Phase 3 UPSTREAM MG trial for telitacicept, a treatment for generalized myasthenia gravis, with results expected in early 2027. The company plans to start a Phase 3 trial for ocular myasthenia gravis in the same timeframe, expanding its telitacicept franchise. The trials follow positive results from RemeGen's Phase 3 trial in China.

Biotech stocks rose as several companies issued updates. Wellgistics Health (WGRX) completed a rebrand to DataMEDS AI and will trade as MEDS; it reported Q1 2026 revenue of $0.929M and expects $1.775M in Q2. Dyadic (DYAI) saw a major shareholder sell. Palvella (PVLA) submitted the first NDA module for QTORIN. Sol-Gel (SLGL) expects SGT-610 Phase 3 data in Q4 2026.

Vor Bio (Nasdaq: VOR) appointed David Zaccardelli, Pharm.D., to its Board of Directors. The company said he has led biopharma companies through late-stage development and commercialization, including Verona Pharma until its Oct 2025 acquisition by Merck for $10B. Vor also noted Andrew Levin stepped down as an advisor.

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K 0001817229 false 0001817229 2026-07-06 2026-07-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 06,

Vor Bio (Nasdaq: VOR) said its Compensation Committee granted inducement awards on July 1, 2026 to seven newly hired employees under Nasdaq Rule 5635(c)(4). Awards include stock options for 71,200 shares (10-year term, $18.39 exercise price) and RSUs for 15,150 shares. Options and RSUs vest over four years subject to continued employment.

Vor Biopharma Inc. (VOR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 vor-ex10_1.htm EX-10.1 EX-10.1 321452236 v8 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan Adopted by the Board of Directors: April 16, 2026 Approved by the Stockholders: June 11, 2026 321452236 v8 Table of Contents Page 1. General. 1 2. Shares Subje

Vor Bio (Nasdaq: VOR) said its Compensation Committee granted inducement awards on June 1, 2026 to 10 newly hired employees under Nasdaq Rule 5635(c)(4). The company issued options for 61,050 shares (10-year term, $14.57 exercise price) and RSUs for 12,900 shares. Both vest over four years, subject to continued employment.

Vor Biopharma Inc. (NASDAQ:VOR) experienced a 17.3% decrease in short interest in April, with the total short interest reaching 4,706,707 shares as of April 15th. This represents 9.7% of the company's float, with a days-to-cover ratio of 3.5 days. The stock was trading up 5.6% at midday, reaching $14.81, while analysts maintain a "Moderate Buy" consensus with an average price target of $50.56.

RA Capital Healthcare Fund LP sold 630,374 shares of Vor Biopharma Inc. (NASDAQ:VOR) common stock for approximately $10.17 million across two transactions in April 2026. Following these sales, RA Capital Healthcare Fund LP retains 2,567,245 shares of Vor Biopharma. The company has recently shifted its focus to autoimmune therapies and initiated a global Phase 3 trial for Sjögren’s disease, while analysts have adjusted price targets but largely maintain positive ratings due to promising drug potential.

RA Capital Management and its affiliated funds have reported a slight reduction in their beneficial ownership of Vor Biopharma (VOR) common stock. Despite recent open-market sales, RA Capital still maintains a significant 19.9% stake in the company, which includes a mix of common shares, common stock warrants, and pre-funded warrants. The firm's ownership is subject to a "Beneficial Ownership Blocker" that limits its exercise of pre-funded warrants to prevent exceeding 19.99% ownership.